8-K: Tonix Pharmaceuticals Research Links Pre-Existing Pain Conditions to Increased Long COVID Risk

Tonix Pharmaceuticals announced research indicating that patients with pre-existing chronic overlapping pain conditions (COPCs) have an increased risk of developing Long COVID symptoms.

Summary

• Tonix Pharmaceuticals announced research findings that suggest a link between pre-existing chronic overlapping pain conditions (COPCs) and an increased risk of Long COVID.
• The research, based on anonymized electronic health records of over 91 million people in the U.S., indicates that prolonged pain can occur after viral infections like influenza, and pre-existing pain can be exacerbated by viral illnesses.
• The study suggests that COPCs and Long COVID may share similar brain processes, with Long COVID potentially being a new onset or exacerbation of a pre-existing COPC.
• The magnitude of Long COVID risk conferred by a pre-existing COPC was comparable with, if not larger than, that for sex and acute COVID hospitalization status.
• Tonix is studying TNX-102 SL (Tonmya) for the management of fibromyalgia and fibromyalgia-type Long COVID.

Sentiment

Score: 7

Explanation: The document presents positive research findings and progress in drug development, but also acknowledges risks and uncertainties. The sentiment is moderately positive due to the potential for Tonix's research to address a significant unmet medical need.

Positives

• The research provides valuable insights into the relationship between pre-existing pain conditions and Long COVID.
• The study utilized a large dataset of over 91 million people, increasing the reliability of the findings.
• Tonix is actively developing TNX-102 SL (Tonmya) for both fibromyalgia and fibromyalgia-type Long COVID, addressing a significant unmet medical need.
• Tonmya has shown positive results in two Phase 3 clinical trials for the management of fibromyalgia.
• Tonix has a broad pipeline of development candidates focused on central nervous system disorders, rare diseases, immunology and infectious diseases.

Negatives

• The research is observational and does not establish a causal relationship between COPCs and Long COVID.
• The study relies on electronic health record data, which may have limitations in terms of accuracy and completeness.
• The development of new drugs is subject to regulatory risks and uncertainties.

Risks

• The company's product development is subject to regulatory risks, including the possibility of not obtaining FDA approval.
• There are risks associated with the commercialization of new products, including market acceptance and competition.
• The company may require additional financing to support its research and development activities.
• There are uncertainties related to patent protection and litigation.
• The company faces competition from other pharmaceutical companies.

Future Outlook

Tonix plans to submit an NDA for Tonmya in the second half of 2024 and is continuing development of its pipeline of therapeutics.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that the results contribute to a growing body of evidence that most symptoms of Long COVID are at least partly driven by central nervous system mechanisms.
• Dr. Lederman also noted that it will be important to learn if appropriate management of fibromyalgia may reduce the risk of developing Long COVID.
• Rachael Bergmans, M.P.H, Ph.D., lead author of the paper, stated that the magnitude of Long COVID risk conferred by a pre-existing COPC was comparable with, if not larger than, that for sex and acute COVID hospitalization status.

Industry Context

This announcement is relevant to the broader pharmaceutical industry's focus on understanding and addressing the long-term effects of COVID-19, particularly the overlap with other chronic conditions. It highlights the potential for existing treatments for conditions like fibromyalgia to be repurposed for Long COVID.

Comparison to Industry Standards

• The use of a large dataset of over 91 million patient records is a significant strength of this study, aligning with industry best practices for large-scale observational research.
• The focus on central nervous system mechanisms in Long COVID is consistent with emerging research in the field.
• Tonix's approach of repurposing TNX-102 SL (Tonmya) for Long COVID is a common strategy in drug development, aiming to leverage existing knowledge and clinical data.
• Other companies are also exploring treatments for Long COVID, but the specific focus on the link with COPCs and the potential for fibromyalgia treatments to be effective is a unique aspect of Tonix's approach.
• The planned NDA submission for Tonmya in the second half of 2024 is a key milestone, and the company's progress will be closely watched by investors and competitors.

Stakeholder Impact

• Shareholders may view the research findings and drug development progress positively.
• Patients with fibromyalgia and Long COVID may benefit from the development of new treatments.
• The company's employees are involved in the research and development efforts.
• The company's suppliers and partners are involved in the manufacturing and distribution of its products.

Next Steps

• Tonix plans to meet with the FDA in the first half of 2024.
• Tonix plans to submit an NDA to the FDA for Tonmya in the second half of 2024.
• A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024.

Key Dates

Keywords

Long COVID, fibromyalgia, chronic overlapping pain conditions, COPCs, TNX-102 SL, Tonmya, clinical trials, NDA, central nervous system disorders, biopharmaceutical